Krystal Moya

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP -Deleted Cancers”.

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP -Deleted Cancers

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.1c01900

N/A

0DataRank · unranked

152 citations

Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen +18 more

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.2c00741

N/A

0DataRank · unranked

95 citations

Jacob R. Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns +21 more

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0870

N/A

0DataRank · unranked

33 citations

Larry Yan, Fadia Qiryaqos, Lars D. Engstrom, Jade Laguer, Andrew Calinisan +29 more